Compare · AZN vs PBYI
AZN vs PBYI
Side-by-side comparison of AstraZeneca PLC (AZN) and Puma Biotechnology Inc (PBYI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and PBYI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $261.92B, about 603.3x PBYI ($434.2M).
- Over the past year, AZN is down 10.3% and PBYI is up 150.7% - PBYI leads by 161.1 points.
- AZN has been more active in the news (15 items in the past 4 weeks vs 5 for PBYI).
- AZN has more recent analyst coverage (25 ratings vs 4 for PBYI).
- Company
- AstraZeneca PLC
- Puma Biotechnology Inc
- Price
- $168.85-0.24%
- $8.53+1.25%
- Market cap
- $261.92B
- $434.2M
- 1M return
- -5.56%
- +18.73%
- 1Y return
- -10.32%
- +150.74%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 15
- 5
- Recent ratings
- 25
- 4
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest PBYI
- President and CEO Auerbach Alan H sold $364,051 worth of shares (44,058 units at $8.26) as part of a pre-agreed trading plan, decreasing direct ownership by 0.60% to 7,261,671 units (SEC Form 4)
- Officer Hunt Douglas M sold $69,905 worth of shares (8,460 units at $8.26) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 196,841 units (SEC Form 4)
- Chief Financial Officer Nougues Maximo F sold $77,557 worth of shares (9,386 units at $8.26) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 230,637 units (SEC Form 4)
- SEC Form 144 filed by Puma Biotechnology Inc
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Wilson Troy Edward was granted 27,000 shares and sold $77,748 worth of shares (10,800 units at $7.20) as part of a pre-agreed trading plan, increasing direct ownership by 37% to 59,750 units (SEC Form 4)
- Director Stuglik Brian M was granted 27,000 shares and sold $58,311 worth of shares (8,100 units at $7.20) as part of a pre-agreed trading plan, increasing direct ownership by 20% to 113,858 units (SEC Form 4)
- Director Senderowicz Adrian sold $194,311 worth of shares (27,000 units at $7.20) as part of a pre-agreed trading plan and was granted 27,000 shares (SEC Form 4)
- Director Miller Michael Patrick was granted 27,000 shares, increasing direct ownership by 50% to 81,000 units (SEC Form 4)